QLQingxing Liu

Qingxing Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qingxing Liu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Zhaohui Zhu

    Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    6 shared publications
  • Fang Li

    Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

    3 shared publications
  • Hao Wang

    Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

    3 shared publications
  • Jie Zang

    Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

    3 shared publications
  • Jingnan Wang

    Department of Nuclear Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

    3 shared publications
  • Orit Jacobson

    Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD

    3 shared publications

Latest Publications

  • Deep learning-based non-invasive prediction of PD-L1 status and immunotherapy survival stratification in esophageal cancer using [18F]FDG PET/CT

    by Fei Xie, Mobei Zhang, Chunhong Zheng, Zhenwei Zhao, Jiarou Wang, Yufan Li, Kai Wang, Wenzhuo Wang, JunJie Lin, Tingting Wu, et al.

    This study aimed to develop and validate deep learning models using [18F]FDG PET/CT to predict PD-L1 status in esophageal cancer (EC) patients. Additionally, we assessed the potential of derived deep learning model scores (DLS) for survival stratification in immunotherapy. In this retrospective study, we included 331 EC patients from two centers, dividing them into training, internal validation, and external validation cohorts. Fifty patients who received immunotherapy were followed up. We developed four 3D ResNet10-based models-PET + CT + clinical factors (CPC), PET + CT (PC), PET (P), and CT (C)-using pre-treatment [18F]FDG PET/CT scans. For comparison, we also constructed a logistic model incorporating clinical factors (clinical model). The DLS were evaluated as radiological markers for survival stratification, and nomograms for predicting survival were constructed. The models demonstrated accurate prediction of PD-L1 status. The areas under the curve (AUCs) for predicting PD-L1 status were as follows: CPC (0.927), PC (0.904), P (0.886), C (0.934), and the clinical model (0.603) in the training cohort; CPC (0.882), PC (0.848), P (0.770), C (0.745), and the clinical model (0.524) in the internal validation cohort; and CPC (0.843), PC (0.806), P (0.759), C (0.667), and the clinical model (0.671) in the external validation cohort. The CPC and PC models exhibited superior predictive performance. Survival analysis revealed that the DLS from most models effectively stratified overall survival and progression-free survival at appropriate cut-off points (P < 0.05), outperforming stratification based on PD-L1 status (combined positive score ≥ 10). Furthermore, incorporating model scores with clinical factors in nomograms enhanced the predictive probability of survival after immunotherapy. Deep learning models based on [18F]FDG PET/CT can accurately predict PD-L1 status in esophageal cancer patients. The derived DLS can effectively stratify survival outcomes following immunotherapy, particularly when combined with clinical factors.


  • Fully automated 3D multi-modal deep learning model for preoperative T-stage prediction of colorectal cancer using 18F-FDG PET/CT

    by Mobei Zhang, Yufan Li, Chunhong Zheng, Fei Xie, Zhenwei Zhao, Fahao Dai, Jiarou Wang, Hubing Wu, Zhaohui Zhu, Qingxing Liu, et al.

    Purpose This study aimed to develop a fully automated 3D multi-modal deep learning model using preoperative 18F-FDG PET/CT to predict the T-stage of colorectal cancer (CRC) and evaluate its clinical utility. Methods A retrospective cohort of 474 CRC patients was included, with 400 patients for internal cohort and 74 patients for external cohort. Patients were classified into early T-stage (T1-T2) and advanced T-stage (T3-T4) groups. Automatic segmentation of the volume of interest (VOI) was achieved based on TotalSegmentator. A 3D ResNet18-based deep learning model integrated with a cross-multi-head attention mechanism was developed. Five models (CT + PET + Clinic (CPC), CT + PET (CP), PET (P), CT (C), Clinic) and two radiologists’ assessment were compared. Performance was evaluated using Area Under the Curve (AUC). Grad-CAM was employed to provide visual interpretability of decision-critical regions. Results The automated segmentation achieved Dice scores of 0.884 (CT) and 0.888 (PET). The CPC and CP models achieved superior performance, with AUCs of 0.869 and 0.869 in the internal validation cohort, respectively, outperforming single-modality models (P: 0.832; C: 0.809; Clinic: 0.728) and the radiologists (AUC: 0.627, P < 0.05 for all models vs. radiologists, except for the Clinical model). External validation exhibited a similar trend, with AUCs of 0.814, 0.812, 0.763, 0.714, 0.663 and 0.704, respectively. Grad-CAM visualization highlighted tumor-centric regions for early T-stage and peri-tumoral tissue infiltration for advanced T-stage. Conclusion The fully automated multimodal, fusing PET/CT with cross-multi-head-attention, improved T-stage prediction in CRC, surpassing the single-modality models and radiologists, offering a time-efficient tool to aid clinical decision-making.


  • Synthesis and preclinical evaluation of [18F]AlF-NOTA-Asp2-PEG2-JR11 as a novel antagonist radioligand for PET imaging of somatostatin receptor

    by Haoran Liang, Zihao Chen, Chunwei Mo, Yanjiang Han, Qingxing Liu, Ganghua Tang

    Purpose Somatostatin receptor (SSTR) antagonists have recently emerged as preferable radiotracers for SSTR-targeted imaging and therapy. This study aimed to design a novel SSTR antagonist, [18F]AlF-NOTA-Asp2-PEG2-JR11, and compare its preclinical performance with the previously reported antagonist, [18F]AlF-NOTA-JR11, and the agonist [68Ga]Ga-DOTA-TATE. Methods [18F]AlF-NOTA-Asp2-PEG2-JR11 was synthesized via a one-step radiolabeling process involving [18F]AlF chelation. The binding affinity, internalization, and cellular uptake were evaluated using AR42J/SSTR + cells. Biodistribution and PET/CT imaging were conducted in mice bearing xenografted AR42J/SSTR + or HCT116/SSTR- tumor xenografts. Results [18F]AlF-NOTA-Asp2-PEG2-JR11 was manually synthesized within 30 min with an uncorrected radiochemical yield of 39.56 ± 3.25% (n > 5) and radiochemical purity (RCP) exceeding 99% (n > 5). [18F]AlF-NOTA-Asp2-PEG2-JR11 demonstrated excellent in vivo stability over 2 h (RCP > 95%). Among AR42J cells, [18F]AlF-NOTA-Asp2-PEG2-JR11 exhibited high affinity, specific uptake, and low internalization, similar to [18F]AlF-NOTA-JR11. Biodistribution and micro-PET/CT imaging studies revealed comparable tumor uptake between [18F]AlF-NOTA-Asp2-PEG2-JR11 and [18F]AlF-NOTA-JR11 (9.26 ± 0.49 vs. 10.18 ± 0.82%ID/g, p = 0.147) at 60 min post-injection (p.i), both were significantly higher than [68Ga]Ga-DOTA-TATE (6.79 ± 0.29%ID/g, p = 0.001). Co-injecting the corresponding inhibitor significantly reduced the tumor uptake of all three tracers. Notably, [18F]AlF-NOTA-Asp2-PEG2-JR11 reached peak tumor uptake at 30 min p.i. and exhibited the lowest uptake and fastest clearance in most normal organs, including the kidney, bone, liver, and muscle, resulting in the highest and increasing tumor-to-background ratios (TBR) over time among the three tracers. Conclusion The synthesis of [18F]AlF-NOTA-Asp2-PEG2-JR11 is efficient, with high radiochemical yield and RCP. [18F]AlF-NOTA-Asp2-PEG2-JR11 exhibits excellent in vivo stability, high tumor uptake, and superior TBR, making it a promising potential tracer for imaging SSTR-positive tumors.


  • Open Access

    Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature

    by Da Zhang, Lin Lu, Hui-Juan Zhu, Yu Xiao, Xian-Lin Han, Shun-Da Du, Hua-Dan Xue, Qing-Xing Liu, Zhao-Hui Zhu, Ming-Ming Hu, et al.

    Objectives. To analyze and summarize the effect of SSA treatment on EAS due to p-NETs (EAS-p-NETs). Methods. Thirteen patients with EAS-p-NETs treated with SSAs at our center or described in the literature were included in this study. Clinical characteristics, laboratory data, imaging studies, histopathologic results, the effect of SSA treatment, and the prognosis of these EAS-p-NET patients were evaluated. Results. Four males and 9 females with an average age of 42.9 years were included in the study. The mean duration of follow-up was 38.8±28.2 months. As one of the combined treatment measures, SSAs controlled the levels of ACTH and cortisol in 9 of the 13 patients (69.2). Partial response was observed in 3 patients (23.1), stable disease in 2 patients (15.4), and progressive disease in 6 patients (46.2). The median time to tumor progression was 24 months, and the median overall survival was 61 months. The side effects of SSA treatment included temporary mild abdominal pain, diarrhea, gallstones, and cholecystitis. Conclusions. As a supplemental therapy, SSA treatment led to clinical and biochemical improvement with a good safety profile in patients exhibiting EAS-p-NET with metastasis. However, tumor progression was inhibited by SSA treatment in only a few patients. Combined with other treatments, SSAs may improve the prognosis of patients with EAS-p-NETs.


  • Open Access

    Solving the Optimal Strategy of “Crossing the Desert” Based on Dynamic Programming

    by Zhou Chen, Qingxing Liu, Yuxiang Cai

    In real life, many practical situations need to maximize the benefits under certain conditions. This paper studies the B problem of the 2020 National College Students Mathematical Modeling Contest. Through the establishment of a mathematical model, a combination of weighted undirected graphs, dynamic programming, computer simulation and multi-person non-cooperative models are used to discuss different conditions. The best decision and maximum benefit. For question one, get the maximum benefit of the first and second levels; for question two, solve the strategies that players should adopt for the third and fourth levels; for question three, it is concluded that players should use under normal circumstances Specific strategies.


  • Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions

    by Jingnan Wang, Jie Zang, Hao Wang, Qingxing Liu, Fang Li, Yansong Lin, Li Huo, Orit Jacobson, Gang Niu, Xinrong Fan, et al.

    Aim: Combined 68Ga-PSMA-617 PET imaging and 177Lu-PSMA-617 therapy is a precise targeted theranostic approach for patients with metastatic castration-resistant prostate cancer (mCRPC). The purpose of this study was to determine whether pretherapeutic standard uptake value (SUV) in 68Ga-PSMA-617 PET could indicate the effective dose in the main organs and absorbed dose in tumor lesions. Methods: After institutional review board approval and informed consent, 9 patients with mCRPC were recruited and underwent 68Ga-PSMA-617 PET/CT scans. Five patients received 177Lu-PSMA-617 (1.30–1.42 GBq, 35–38.4 mCi) and then underwent serial whole-body planar imaging and SPECT/CT imaging of both thoracic and abdominal regions at 0.5-, 2-, 24-, 48-, and 72-hour time points. The other 4 patients received 177Lu-EB-PSMA-617 (0.80–1.1 GBq, 21.5–30 mCi) and then underwent the same imaging procedures at 2-, 24-, 72-, 120-, and 168-hour time points. The effective dose in the main organs and the absorbed dose in tumor lesions were calculated. Detailed correlations between the pretherapeutic SUV in 68Ga-PSMA-617 PET and effective dose in the main organs as well as absorbed dose in the tumor lesions were analyzed. Results: SUV of 68Ga-PSMA-617 PET was moderately correlated with effective dose in main organs (r = 0.610 for 177Lu-PSMA-617, r = 0.743 for 177Lu-EB-PSMA-617, both P < 0.001). SUV of tumor lesions in 68Ga-PSMA-617 PET had high correlation with those in 177Lu-PSMA-617 (r = 0.915, P < 0.001) and moderate correlation with those in 177Lu-EB-PSMA-617 (r = 0.611, P = 0.002). Conclusions: Pretherapeutic 68Ga-PSMA-617 PET may indicate the dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617. Both the effective dose in main organs and absorbed dose in tumor lesions correlate with SUV of 68Ga-PSMA-617 PET. This relationship may help select appropriate candidates for peptide receptor radionuclide therapy. Further investigations of larger cohorts are needed to confirm these initial findings.


  • First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer

    by Jie Zang, Xinrong Fan, Hao Wang, Qingxing Liu, Jingnan Wang, Hui Li, Fang Li, Orit Jacobson, Gang Niu, Zhaohui Zhu, et al.

    This translational study is designed to assess the safety, dosimetry and therapeutic response to a single, low-dose of 177Lu-EB-PSMA-617 in comparison to 177Lu-PSMA-617 in patients with mCRPC.


  • Open Access

    Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study

    by Hao Wang, Yuejuan Cheng, Jingjing Zhang, Jie Zang, Hui Li, Qingxing Liu, Jingnan Wang, Orit Jacobson, Fang Li, Zhaohui Zhu, et al.

    Objective: 177Lu-DOTA-EB-TATE is a theranostic agent based on octreotate that uses an Evans blue structure to bind albumin to improve the pharmacokinetics and pharmacodynamics. This pilot study aims to evaluate the efficacy of a single low-dose treatment using 177Lu-DOTA-EB-TATE in patients with advanced neuroendocrine neoplasm (NEN).


  • Neutrophil–lymphocyte ratio is a reliable predictive marker for early‐stage diabetic nephropathy

    by Wanjing Huang, Jinhua Huang, Qingxing Liu, Fuchuan Lin, Zhihao He, Zhenhua Zeng, Lei He

    Summary: Introduction: Diabetic nephropathy (DN) is a common complication in diabetics. Recent evidence suggests that neutrophil–lymphocyte ratio (NLR) affects the development and acceleration of some diabetic complications. Scholars have rarely investigated the relationship between DN and NLR. This study aims to evaluate the relationship between DN and NLR and estimate whether or not NLR is a reliable marker for early‐stage DN.Patients and methods: The study included 253 patients with type 2 diabetes mellitus, 115 of whom have early‐stage DN. The control group was composed of 210 healthy age‐ and sex‐matched subjects.Results: The NLR values of the patients with diabetes were significantly higher than those of the healthy controls (P < 0·001), and the NLR values of the patients with early‐stage DN were higher than those of the patients without DN (P < 0·001). Logistic regression analysis showed that the risk predictors of DN include NLR, creatinine, total cholesterol, systolic blood pressure, HbA1c and insulin resistance. NLR (P = 0·004, EXP(B) = 2·088, 95% CI = 1·271–3·429) levels positively correlated with DN. The DN odds ratio increased by a factor of 2·088 (95% CI, 1·271–3·429) for every one unit increase in NLR.Conclusions: Increased NLR was significantly associated with DN, and high NLR values may be a reliable predictive marker of early‐stage DN.